Skip to Main Content

Author Details

Debyani Chakravarty
Memorial Sloan Kettering Cancer Center
2002
53
30
PMIDPaper TitleJournal TitlePublished Year
37849038Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer.Cancer Discov2024
37651310Molecular Characterization of Endometrial Carcinomas in Black and White Patients Reveals Disparate Drivers with Therapeutic Implications.Cancer Discov2023
38084089Precision Oncology: 2023 in Review.Cancer Discov2023
37898613Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing.Nat Commun2023
37890492Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers.Cancer Cell2023
35165384Base editing sensor libraries for high-throughput engineering and functional analysis of cancer-associated single nucleotide variants.Nat Biotechnol2022
35440569AKT mutant allele-specific activation dictates pharmacologic sensitivities.Nat Commun2022
35796744Response to Mehta et al.Genet Med2022
36458431Precision Oncology: 2022 in Review.Cancer Discov2022
36357680Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.Nat Med2022
36063163Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC).Genet Med2022
36228155Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention.Clin Cancer Res2022
36048199Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort.Cancer Discov2022
35101336Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC).Genet Med2022
35066956Computational methods and translational applications for targeted next-generation sequencing platforms.Genes Chromosomes Cancer2022
35175857Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.J Clin Oncol2022
34059130Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.Genome Med2021
33625877OncoTree: A Cancer Classification System for Precision Oncology.JCO Clin Cancer Inform2021
33762738Clinical cancer genomic profiling.Nat Rev Genet2021
35072136GA4GH: International policies and standards for data sharing across genomic research and healthcare.Cell Genom2021
34133209Therapeutic Implications of Germline Testing in Patients With Advanced Cancers.J Clin Oncol2021
34351646Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.Cancer2021
32193223The Evolutionary Origins of Recurrent Pancreatic Cancer.Cancer Discov2020
32644817Collaborative, Multidisciplinary Evaluation of Cancer Variants Through Virtual Molecular Tumor Boards Informs Local Clinical Practices.JCO Clin Cancer Inform2020
32721511RAS/MAPK Pathway Driver Alterations Are Significantly Associated With Oncogenic KIT Mutations in Germ-cell Tumors.Urology2020
32246132A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer.Nat Genet2020
31152158Publisher Correction: The long tail of oncogenic drivers in prostate cancer.Nat Genet2019
32914018Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology.JCO Precis Oncol2019
32914011Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets.JCO Precis Oncol2019
31175097Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations.Clin Cancer Res2019
29247016Accelerating Discovery of Functional Mutant Alleles in Cancer.Cancer Discov2018
30137196A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).Ann Oncol2018
30311369Integrating somatic variant data and biomarkers for germline variant classification in cancer predisposition genes.Hum Mutat2018
29610475The long tail of oncogenic drivers in prostate cancer.Nat Genet2018
29683790Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.J Clin Oncol2018
29625050Oncogenic Signaling Pathways in The Cancer Genome Atlas.Cell2018
27442865The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform.JAMA Oncol2017
28336552Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.Cancer Discov2017
28481359Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.Nat Med2017
28472509Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.Neuro Oncol2017
29045506Clinical and molecular characterization of patients with cancer of unknown primary in the modern era.Ann Oncol2017
28777785Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.Nat Med2017
28911072Oncologist use and perception of large panel next-generation tumor sequencing.Ann Oncol2017
28831081EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines.Sci Rep2017
28825054Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.JCO Precis Oncol2017
28890946OncoKB: A Precision Oncology Knowledge Base.JCO Precis Oncol2017
27807832Transcriptome and Proteome Analyses of TNFAIP8 Knockdown Cancer Cells Reveal New Insights into Molecular Determinants of Cell Survival and Tumor Progression.Methods Mol Biol2017
24120142The somatic genomic landscape of glioblastoma.Cell2013
22323597Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.Proc Natl Acad Sci U S A2012
22105174Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.J Clin Invest2011
  • 1 - 50 of 53

Recommended Authors

National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ)
Career Start Year 2016
Number of shared co-authors 7
Washington University in St. Louis School of Medicine
Career Start Year 2015
Number of shared co-authors 25
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 2014
Number of shared co-authors 22
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2014
Number of shared co-authors 18
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 2014
Number of shared co-authors 25
The University of Texas MD Anderson Cancer Center
Career Start Year 2014
Number of shared co-authors 45
Broad Institute of MIT and Harvard
Career Start Year 2013
Number of shared co-authors 47
Nanjing Geneseeq Technology Inc.
Career Start Year 2012
Number of shared co-authors 0
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 19
The Netherlands Cancer Institute
Career Start Year 2008
Number of shared co-authors 2
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2007
Number of shared co-authors 7
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 2007
Number of shared co-authors 1
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 3
Tokyo Medical and Dental University Hospital
Career Start Year 2006
Number of shared co-authors 2
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 45
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2003
Number of shared co-authors 36
Present Address: Tempus Labs Inc.
Career Start Year 2003
Number of shared co-authors 7
Foundation Medicine Inc
Career Start Year 2003
Number of shared co-authors 6
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 1
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2001
Number of shared co-authors 9
Dana-Farber Cancer Institute
Career Start Year 2000
Number of shared co-authors 35
Department of Medicine and Moores Cancer Center, University of California San Diego
Career Start Year 2000
Number of shared co-authors 1
Erasmus MC Cancer Institute
Career Start Year 1999
Number of shared co-authors 15
The University of Texas MD Anderson Cancer Center
Career Start Year 1999
Number of shared co-authors 49
Massachusetts General Hospital
Career Start Year 1997
Number of shared co-authors 26
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Career Start Year 1996
Number of shared co-authors 15
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 9
Foundation Medicine
Career Start Year 1995
Number of shared co-authors 20
Wellcome Sanger Institute
Career Start Year 1993
Number of shared co-authors 14
University of California San Diego Moores Cancer Center
Career Start Year 1992
Number of shared co-authors 1

Collaborators

Memorial Sloan Kettering Cancer Center
Co-authored papers 23
Co-authored papers 20
Memorial Sloan Kettering Cancer Center
Co-authored papers 18
Memorial Sloan Kettering Cancer Center
Co-authored papers 16
Memorial Sloan Kettering Cancer Center
Co-authored papers 14
Memorial Sloan Kettering Cancer Center
Co-authored papers 10
Memorial Sloan Kettering Cancer Center
Co-authored papers 9
Memorial Sloan Kettering Cancer Center
Co-authored papers 8
Memorial Sloan Kettering Cancer Center
Co-authored papers 7
Memorial Sloan Kettering Cancer Center
Co-authored papers 7
Co-authored papers 6
Memorial Sloan Kettering Cancer Center
Co-authored papers 5
Iowa State University, Mayo Clinic, Nationwide Children's Hospital, The Ohio State University College of Medicine, University of Iowa, Washington University in Saint Louis
Co-authored papers 5
National Cancer Institute
Co-authored papers 5
Co-authored papers 5
Washington University
Co-authored papers 5
Washington University
Co-authored papers 5
Mayo Clinic
Co-authored papers 4
Innovation Center for Biomedical Informatics, Georgetown University Medical Center
Co-authored papers 4
University of Cuenca
Co-authored papers 4
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Co-authored papers 4
Co-authored papers 4
Oncology R&D
Co-authored papers 4
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Dana-Farber Cancer Institute
Co-authored papers 4
Baylor College of Medicine
Co-authored papers 4
Vanderbilt University Medical Center
Co-authored papers 4
Boston University
Co-authored papers 4
Memorial Sloan Kettering Cancer Center
Co-authored papers 3